Security
MiNK Therapeutics, Inc. Common Stock · INKT
INKTNASDAQCommon stockCurrentCIK 1840229Updated Oct 15, 2026
Name history
AgenTus Therapeutics, Inc. · through Mar 18, 2021AgenTus Therapeutics, Inc. · through Mar 18, 2021
INKT price & chart
Loading TradingView…
NASDAQ:INKT on TradingView ↗About the company
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic iNKT cell therapies for life-threatening conditions driven by immune dysfunction. The company's lead program, agenT-797, is being evaluated in acute lung injury and critical illness, with a pipeline that extends across immuno-oncology, transplant medicine, and other settings where dysregulated immunity is a driver of morbidity and mortality. MiNK believes that iNKT cell biology, because of its regulatory role across innate and adaptive immunity, may represent a foundational approach to immune restoration applicable across a broad range of conditions. For more information, visit www.minktherapeutics.com.
In the news
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 14,963,665Source | 7,374,742Source | 9,615,242Source | 2,484,417Source | 10,323,598Source | 10,376,972Source | 4,267,313Source | 6,893,943Source | 14,238,842Source | 5,720,813Source | 4,552,281Source | 21,471,602Source |
| Property, Plant and Equipment, NetUSD | 429,344Source | 799,522Source | 318,474Source | 473,215Source | 849,957Source | 354,518Source | 687,500Source | 894,992Source | 390,869Source | 732,929Source | 953,977Source | 1,066,910Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 14,281,212Source | 6,328,239Source | 8,806,977Source | 1,681,915Source | 9,313,668Source | 9,525,676Source | 3,234,899Source | 5,817,080Source | 13,360,340Source | 4,577,040Source | 3,367,229Source | 19,635,725Source |
| Assets, CurrentUSD | 14,534,321Source | 6,575,220Source | 9,296,768Source | 2,011,202Source | 9,473,641Source | 10,022,454Source | 3,579,813Source | 5,998,951Source | 13,847,973Source | 4,987,884Source | 3,598,304Source | 20,404,692Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 46Source | 395Source | 52Source | 40Source | 394Source | 51Source | 40Source | 347Source | 48Source | 40Source | 346Source | 339Source |
| Retained Earnings (Accumulated Deficit)USD | -154,073,892Source | -141,718,631Source | -162,546,564Source | -151,186,183Source | -139,912,034Source | -159,418,363Source | -146,948,432Source | -137,210,228Source | -156,675,995Source | -144,181,735Source | -133,396,933Source | -110,939,074Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -692,114Source | -672,838Source | -699,892Source | -719,318Source | -611,375Source | -697,426Source | -662,441Source | -385,780Source | -718,916Source | -631,576Source | -430,947Source | -292,468Source |
| Stockholders' Equity Attributable to ParentUSD | -13,512,982Source | -17,554,089Source | -14,028,296Source | -25,189,315Source | -16,576,143Source | -12,685,989Source | -21,791,779Source | -20,299,207Source | -14,227,659Source | -19,585,882Source | -18,055,449Source | -401,303Source |
| Additional Paid in Capital, Common StockUSD | 141,252,978Source | 124,836,985Source | 149,218,108Source | 126,716,146Source | 123,946,872Source | 147,429,749Source | 125,819,054Source | 117,296,454Source | 143,167,204Source | 125,227,389Source | 115,772,085Source | 110,829,900Source |
| Liabilities and EquityUSD | 14,963,665Source | 7,374,742Source | 9,615,242Source | 2,484,417Source | 10,323,598Source | 10,376,972Source | 4,267,313Source | 6,893,943Source | 14,238,842Source | 5,720,813Source | 4,552,281Source | 21,471,602Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 13,433,554Source | 7,398,993Source | 7,568,743Source | 13,163,565Source | 10,147,359Source | 7,287,425Source | 12,120,067Source | 11,108,260Source | 13,031,448Source | 6,959,676Source | 11,402,585Source | 12,683,166Source |
| Accounts Payable, CurrentUSD | 3,693,115Source | 2,361,175Source | 3,918,739Source | 3,314,839Source | 3,202,146Source | 3,391,418Source | 2,661,195Source | 3,486,999Source | 3,425,314Source | 2,728,212Source | 3,911,973Source | 5,823,000Source |
| Other Liabilities, NoncurrentUSD | — | 2,942Source | — | — | 23,280Source | — | — | 31,600Source | — | 0Source | 48,072Source | 108,500Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,256,965Source | 2,645,494Source | 1,195,746Source | 1,861,464Source | 4,626,711Source | 1,326,265Source | 1,971,023Source | 5,282,707Source | 1,579,147Source | 1,873,561Source | 5,037,361Source | 4,238,555Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -2,742,368Source | -2,766,697Source | -12,494,260Source | -10,784,802Source | -22,457,859Source | -27,991,212Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 630,386Source | 591,089Source | 2,673,997Source | 1,810,226Source | 3,860,366Source | 3,026,846Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -32,414Source | -68,606Source | 689,710Source | -1,182,414Source | -1,917,557Source | 2,660,769Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,732,597Source | -1,340,876Source | -5,925,168Source | -9,555,476Source | -15,762,512Source | -18,866,843Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | -73,561Source | -250,046Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 73,561Source | 250,046Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -2,100,830Source | 576Source | 14,721,897Source | 10,819,986Source | -407,173Source | -155,599Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,834,664Source | -1,342,141Source | 8,783,300Source | 1,209,811Source | -16,268,496Source | -19,253,103Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 14,281,212Source | 6,328,239Source | 8,806,977Source | 1,681,915Source | 9,525,676Source | 3,234,899Source | 13,360,340Source | 4,577,040Source | 3,367,229Source | 19,635,725Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 3,824Source | 3,680Source | 9,516Source | 13,135Source | 27,509Source | 10,820Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -1,237Source | -1,841Source | -13,429Source | -54,699Source | -25,250Source | 19,385Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 621,000Source | 883,000Source | 422,000Source | 897,000Source | 630,000Source | 571,000Source | 2,652,000Source | 2,842,000Source | 3,830,000Source | 3,027,000Source |
| Deconsolidation, Gain (Loss), AmountUSD | — | — | — | — | — | — | — | — | — | 185,351Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 36,066Source | 50,765Source | 181,745Source | 215,437Source | 204,617Source | 121,749Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | — | -14,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | -169,800Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 1,846,495Source | 1,163,033Source | 1,329,726Source | 1,849,130Source | 1,677,697Source | 1,270,863Source | 6,729,817Source | 4,314,164Source | 7,431,108Source | 7,834,155Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,887,709Source | -1,806,597Source | -3,128,201Source | -4,237,751Source | -2,742,368Source | -2,766,697Source | -12,494,260Source | -10,784,802Source | -22,457,859Source | -27,991,212Source |
| Other Nonoperating Income (Expense)USD | — | — | 240,734Source | — | 15,809Source | -185,703Source | 58,585Source | -79,527Source | -32,370Source | 330,915Source | -10Source | 2,704,743Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 1,595Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -3,183,594Source | -1,884,612Source | -3,216,894Source | -4,052,396Source | -2,881,787Source | -2,700,687Source | -12,642,136Source | -11,288,285Source | -22,921,105Source | -30,949,278Source |
| Other Nonoperating Income (Expense)USD | — | — | 240,734Source | — | 15,809Source | -185,703Source | 58,585Source | -79,527Source | -32,370Source | 330,915Source | -10Source | 2,704,743Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,887,709Source | -1,806,597Source | -3,128,201Source | -4,237,751Source | -2,742,368Source | -2,766,697Source | -12,494,260Source | -10,784,802Source | -22,457,859Source | -27,991,212Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.65Source | -0.46Source | -0.62Source | -1.06Source | -0.57Source | -0.7Source | -2.93Source | -2.86Source | -0.65Source | -0.83Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.65Source | -0.46Source | -0.62Source | -1.06Source | -0.57Source | -0.7Source | -2.93Source | -2.86Source | -0.65Source | -0.83Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 4,443,262Source | 3,953,370Source | 5,023,450Source | 3,981,992Source | 4,797,833Source | 3,964,982Source | 4,270,470Source | 3,773,326Source | 34,359,945Source | 33,672,927Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 4,443,262Source | 3,953,370Source | 5,023,450Source | 3,981,992Source | 4,797,833Source | 3,964,982Source | 4,270,470Source | 3,773,326Source | 34,359,945Source | 33,672,927Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | — | -14,000Source |
| General and Administrative ExpenseUSD | — | — | 1,846,495Source | 1,163,033Source | 1,329,726Source | 1,849,130Source | 1,677,697Source | 1,270,863Source | 6,729,817Source | 4,314,164Source | 7,431,108Source | 7,834,155Source |
| Interest ExpenseUSD | — | — | -25,000Source | -28,000Source | -2,000Source | -27,000Source | -4,000Source | -29,000Source | -110,000Source | -93,000Source | — | — |
| Interest Income (Expense), NetUSD | — | — | 55,151Source | 78,015Source | 72,884Source | 348Source | 80,834Source | 13,517Source | 180,246Source | 172,568Source | 463,256Source | 253,323Source |
| Labor and Related ExpenseUSD | — | — | -913,000Source | -1,217,000Source | -907,000Source | -997,000Source | -878,000Source | -1,027,000Source | -4,237,000Source | -5,217,000Source | — | — |
| Other Cost and Expense, OperatingUSD | — | — | 1,080,000Source | 1,006,000Source | 560,000Source | 1,740,000Source | 595,000Source | 1,030,000Source | 3,949,000Source | 3,619,000Source | — | — |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | 331,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 1,143,178Source | 540,638Source | 1,887,168Source | 1,839,176Source | 1,204,090Source | 1,261,902Source | 5,757,487Source | 6,336,075Source | 15,489,997Source | 23,115,123Source |
| Other Expenses | — | — | — | — | — | — | — | —Source | — | — | — | — |
Filing attachments
inkt-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 inkt-ex99_1.htm EX-99.1 EX-99.1 MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury • First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, infection control, and liberation from ventilator and vasopressor support • Serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated …
Read attachment ↗inkt-ex99_1.htm · 8-K · 2026-05-15
EX-99.1 2 inkt-ex99_1.htm EX-99.1 EX-99.1 MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation • Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 • AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung disease • Non-dilutive …
Read attachment ↗inkt-ex99_1.htm · 8-K · 2026-03-31
EX-99.1 2 inkt-ex99_1.htm EX-99.1 EX-99.1 MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum • ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000 - 300,000 patients annually in US/EU • C-Further Consortium collaboration adds to growing non-dilutive funding for PRAME-TCR iNKT in pediatric oncology • NIH STTR grant and Mary Gooze philanthropic award fully fun…
Read attachment ↗